Binex Co Ltd 053030
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- KRW 13,420.00–14,120.00
- 52-Week Range
- —–—
- Bid/Ask
- KRW 13,810.00 / KRW 13,460.00
- Market Cap
- KRW 415.32 Bil
- Volume/Avg
- 613,057 / 2.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- 270.55
- Price/Sales
- 2.84
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Binex Co Ltd is engaged in manufacturing and distribution of pharmaceutical products. The key products include gastrointestinal (GI) tract regulators and antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, as well as an ointment, creams, and others. It also manufactures biomedicines and raw materials. Its other business operation involved contract development and manufacturing business for other companies. The company invests in some bio ventures that develop biomedicines.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 598
- Website
- http://www.bi-nex.co.kr
Comparables
Valuation
|
Metric
|
053030
|
140410
|
000250
|
|---|---|---|---|
Price/Earnings (Normalized) | 270.55 | — | 1,133.69 |
Price/Book Value | 2.31 | 21.62 | 12.00 |
Price/Sales | 2.84 | 33.52 | 13.77 |
Price/Cash Flow | 60.18 | — | 116.89 |
Price/Earnings
053030
140410
000250
Financial Strength
|
Metric
|
053030
|
140410
|
000250
|
|---|---|---|---|
Quick Ratio | 0.65 | 2.17 | 2.21 |
Current Ratio | 1.09 | 2.51 | 2.83 |
Interest Coverage | 2.91 | −43.24 | −1.85 |
Quick Ratio
053030
140410
000250
Profitability
|
Metric
|
053030
|
140410
|
000250
|
|---|---|---|---|
Return on Assets (Normalized) | 1.63% | −17.65% | 2.87% |
Return on Equity (Normalized) | 2.48% | −33.91% | 5.77% |
Return on Invested Capital (Normalized) | 2.13% | −28.13% | 3.21% |
Return on Assets
053030
140410
000250
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wjdbkmpct | Nbvp | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vdhhspdnc | Nbwzh | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xlbpkrcr | Bmtpdn | $103.7 Bil | |
MRNA
| Moderna Inc | Mvdfzkdz | Dclf | $47.9 Bil | |
ARGX
| argenx SE ADR | Nprxycqm | Rqrd | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Hnnqcyw | Nwntl | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gkmvnybc | Bykfcf | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rndstbvx | Ywftkm | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hsfdqgrzx | Gllvl | $12.8 Bil | |
INCY
| Incyte Corp | Qpvrrlrj | Qrjbzqv | $12.1 Bil |